AMARIN CORP PLC\UK AMRN

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

This Annual Report on Form 10-K, or Annual Report, includes the registered and unregistered trademarks and service marks of other parties.

Amarin Corporation plc is a public limited company incorporated under the laws of England and Wales. Amarin Corporation plc was originally incorporated in England as a private limited company on March 1, 1989 under the Companies Act 1985, and re-registered in England as a public limited company on March 19, 1993.

Our principal office is located at One Central Plaza, 8th Floor, 36 Dame Street, Dublin 2, Ireland. Our registered office is located at One New Change, London EC4M 9AF, England. Our primary office in the United States is located at 440 Route 22, Bridgewater, NJ 08807, USA. Our telephone number at that location is (908) 719-1315.

Last close 11.79 2026-10-23
Market cap —
52-week range 11.25 - 19.24

No market cap here: AMRN is a depositary receipt for shares held in this company's home market, and the number of shares one receipt stands for could not be read from its latest 10-K cover page. Without it, the share count SEC publishes and the price quoted here count different things, and multiplying them would not be this company's value. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.09

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $213.6M$228.6M$306.9M$369.2M$583.2M$614.1M$429.8M$229.2M$181.1M$130.1M
Cost of revenue ————$121.3M$131.4M$96.0M$54.5M$45.0M$34.4M
Gross profit $120.9M$81.4M$165.5M$242.5M$461.9M$482.6M$333.7M$174.7M$136.2M$95.7M
R&D $19.8M$20.9M$22.2M$30.4M$29.3M$39.0M$34.4M$55.9M$47.2M$50.0M
SG&A $115.0M$152.3M$199.9M$304.4M$408.3M$463.3M$323.6M$227.0M$134.5M$111.4M
Total operating expenses $171.0M$173.2M$233.1M$348.4M$451.4M$502.3M$358.0M$282.9M$181.7M$161.3M
Operating income -$50.2M-$91.8M-$67.6M-$105.9M$10.5M-$19.7M-$24.3M-$108.2M-$45.6M-$65.6M
Interest expense $7.0K$7.0K$8.0K$15.0K$129.0K$2.6M$6.6M$8.9M$9.8M$18.7M
Pre-tax income -$36.0M-$77.2M-$53.7M-$103.8M$11.3M-$17.3M-$22.5M-$116.3M-$54.8M-$76.4M
Income tax $2.8M$5.0M$5.4M$2.0M$3.6M$745.0K$164.0K$96.0K$13.0M$10.0M
Net income -$38.8M-$87.0M-$55.0M-$105.8M$7.7M-$18.0M-$22.6M-$116.4M-$67.9M-$86.3M
EPS, basic -0.09-0.20-0.15-0.260.02-0.05-0.07-0.39-0.25-0.41
EPS, diluted -0.09-0.20-0.15-0.260.02-0.05-0.07-0.39-0.25-0.41
Shares, diluted (wtd. avg.) 415.0M410.9M407.7M401.2M402.5M381.8M342.5M297.2M270.7M211.9M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $134.7M$121.0M$199.3M$217.7M$219.5M$187.0M$644.6M$249.2M$73.6M$98.3M
Short-term investments $167.9M$173.2M$121.4M$91.7M$234.7M$314.0M————
Receivables $126.8M$122.3M$133.6M$131.0M$163.7M$154.6M$116.4M$66.5M$45.3M$20.0M
Inventory $195.9M$166.0M$258.6M$228.7M$234.7M$188.9M$76.8M$57.8M$30.3M$20.5M
Total current assets $649.9M$595.4M$725.0M$689.1M$878.7M$879.2M$855.0M$378.0M$153.3M$146.3M
Property, plant and equipment $12.0K$16.0K$114.0K$874.0K$1.4M$2.0M$2.4M$63.0K$28.0K$78.0K
Other intangibles $13.4M$16.4M$19.3M$21.8M$23.5M$13.8M$15.3M$7.5M$8.1M$8.8M
Total assets $670.8M$685.3M$831.7M$886.2M$1.07B$966.0M$882.2M$385.7M$161.6M$167.0M
Accounts payable $45.4M$40.4M$52.8M$64.6M$114.9M$105.9M$50.0M$37.6M$25.2M$6.1M
Short-term debt ————$0$0$50.1M$34.2M$22.3M$15.9M
Total current liabilities $194.5M$179.9M$259.3M$259.5M$370.7M$307.4M$242.2M$157.3M$108.5M$76.2M
Long-term debt ——————$49.7M$46.1M$70.8M$85.2M
Total liabilities $211.5M$199.2M$279.6M$290.8M$401.0M$338.5M$273.9M$233.4M$226.7M$176.1M
Retained earnings -$1.71B-$1.67B-$1.59B-$1.53B-$1.42B-$1.43B-$1.41B-$1.39B-$1.27B-$1.20B
Total equity $459.3M$486.2M$552.1M$595.3M$667.1M$627.5M$608.3M$152.3M-$65.1M-$9.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $6.7M-$31.0M$6.9M-$180.1M-$66.5M-$21.7M-$9.4M-$94.7M-$32.8M-$71.8M
Depreciation and amortisation —$100.0K$200.0K$600.0K$600.0K$600.0K$200.0K—$100.0K$100.0K
Stock-based compensation $13.9M$17.7M$15.6M$26.2M$36.9M$45.8M$30.9M$18.8M$14.0M$13.6M
Capital expenditure —————$252.0K$2.5M$58.0K$12.0K$21.0K
Investing cash flow $8.8M-$46.0M-$25.5M$175.3M$104.1M-$377.0M-$2.5M-$58.0K-$12.0K-$21.0K
Financing cash flow -$2.0M-$1.4M$230.0K-$379.0K-$5.1M-$58.9M$409.6M$271.3M$8.2M$63.1M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-151417.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M 0 200M 400M 600M 800M Revenue, FY2016: 130.1M Gross profit, FY2016: 95.7M Net income, FY2016: -86.3M Revenue, FY2017: 181.1M Gross profit, FY2017: 136.2M Net income, FY2017: -67.9M Revenue, FY2018: 229.2M Gross profit, FY2018: 174.7M Net income, FY2018: -116.4M Revenue, FY2019: 429.8M Gross profit, FY2019: 333.7M Net income, FY2019: -22.6M Revenue, FY2020: 614.1M Gross profit, FY2020: 482.6M Net income, FY2020: -18M Revenue, FY2021: 583.2M Gross profit, FY2021: 461.9M Net income, FY2021: 7.7M Revenue, FY2022: 369.2M Gross profit, FY2022: 242.5M Net income, FY2022: -105.8M Revenue, FY2023: 306.9M Gross profit, FY2023: 165.5M Net income, FY2023: -55M Revenue, FY2024: 228.6M Gross profit, FY2024: 81.4M Net income, FY2024: -87M Revenue, FY2025: 213.6M Gross profit, FY2025: 120.9M Net income, FY2025: -38.8M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $130.1M $181.1M $229.2M $429.8M $614.1M $583.2M $369.2M $306.9M $228.6M $213.6M
Gross profit $95.7M $136.2M $174.7M $333.7M $482.6M $461.9M $242.5M $165.5M $81.4M $120.9M
Net income -$86.3M -$67.9M -$116.4M -$22.6M -$18.0M $7.7M -$105.8M -$55.0M -$87.0M -$38.8M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%